8-K 1 a04-12144_18k.htm 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

October 26, 2004

Date of Report (Date of
earliest event reported)

 

NeoRx Corporation

(Exact Name of Registrant as Specified in Charter)

 

Washington

 

0-16614

 

91-1261311

(State or Other Jurisdiction
of Incorporation)

 

(Commission File No.)

 

(IRS Employer
Identification No.)

 

 

 

 

 

300 Elliot Avenue West, Suite 500, Seattle, WA

 

98119

(Address of principal executive offices)

 

(Zip Code)

 

 

 

 

 

(206) 281-7001

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 8.01.                                          Other Events.

 

On October 26, 2004 NeoRx Corporation issued a press release announcing that it filed an investigational new drug application with the U.S. Food and Drug Administration for a Phase II clinical trial of NX 473, the Company’s next generation platinum product candidate, in patients with small cell lung cancer.  A copy of the press release is attached as Exhibit 99.1 to this report and is hereby incorporated by reference.

 

Item 9.01.              Financial Statements and Exhibits.

 

(c)                                  Exhibits.

 

Exhibit 99.1

 

Press release dated October 26, 2004.

 

1


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

NeoRx Corporation

 

 

 

 

 

Dated: October 26, 2004

By:

/s/ Michael K. Jackson 

 

 

 

Michael K. Jackson 

 

 

Corporate Controller and Chief Accounting Officer

 

2


 

EXHIBIT INDEX

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release dated October 26, 2004.

 

3